RESUMO
PURPOSE OF THE STUDY Ewing sarcomas (ES) are the second most common solid malignant bone tumors in both, children and adolescents, and systemic chemotherapy protocols were established during the last 3 decades which proved to be a successful approach in addition to local treatment. The purpose of the present study is (i) to provide survival rates and prognostic factors for patients with ES which received treatment in a single center and (ii) to compare data with results of multicenter studies. MATERIALS AND METHODS Patients (n = 38) were treated by the same surgeon whereas surgery was combined with radiotherapy in 55.3% of the patients (n = 21). Median age at diagnosis was 17.5 years (4.7-60) and the median follow-up time for all patients was 8.2 years (9.8 years for survivors, 3.2 years for non-survivors). RESULTS The survival rate for metastasis free sarcoma decreases from 90.5% to 50% for patients diagnosed with disseminated disease stage. Patients with a good response to chemotherapy survived in 83.3% of the cases. In addition, a higher OS was found for patients younger than 15 years (82.4%) when compared to patients older than 15 years (73.3%). In contrast, multicenter studies reported lower survival rates for metastasis free (~60%) and metastasis stages (< 40%). DISCUSSION The survival rates in the present single center study are higher than the rates reported from multi-center studies although same chemotherapy protocols were used and no substantially difference are apparent for patient population. CONCLUSIONS Based on the present data we re-emphasize that patients with Ewing sarcoma receive appropriate treatment in a large and qualified center particularly considering the survival rates. In addition, our data underline that a close collaboration between the oncological team and the experienced surgeon is crucial for patient's care. Key words: Ewing sarcoma, survival rate, single center, prognostic factors, chemotherapy, surgery, multi center, single center.
Assuntos
Neoplasias Ósseas/terapia , Sarcoma de Ewing/terapia , Adolescente , Adulto , Fatores Etários , Quimioterapia Adjuvante , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Prognóstico , Radioterapia Adjuvante , Sarcoma de Ewing/secundário , Análise de Sobrevida , Resultado do Tratamento , Adulto JovemRESUMO
The Swiss National Registry for Primary Immunodeficiency Disorders (PID) was established in 2008, constituting a nationwide network of paediatric and adult departments involved in the care of patients with PID at university medical centres, affiliated teaching hospitals and medical institutions. The registry collects anonymized clinical and genetic information on PID patients and is set up within the framework of the European database for PID, run by the European Society of Immunodeficiency Diseases. To date, a total of 348 patients are registered in Switzerland, indicating an estimated minimal prevalence of 4·2 patients per 100 000 inhabitants. Distribution of different PID categories, age and gender are similar to the European cohort of currently 19 091 registered patients: 'predominantly antibody disorders' are the most common diseases observed (n = 217/348, 62%), followed by 'phagocytic disorders' (n = 31/348, 9%). As expected, 'predominantly antibody disorders' are more prevalent in adults than in children (78 versus 31%). Within this category, 'common variable immunodeficiency disorder' (CVID) is the most prevalent PID (n = 98/217, 45%), followed by 'other hypogammaglobulinaemias' (i.e. a group of non-classified hypogammaglobulinaemias) (n = 54/217, 25%). Among 'phagocytic disorders', 'chronic granulomatous disease' is the most prevalent PID (n = 27/31, 87%). The diagnostic delay between onset of symptoms and diagnosis is high, with a median of 6 years for CVID and more than 3 years for 'other hypogammaglobulinaemias'.
Assuntos
Agamaglobulinemia/epidemiologia , Imunodeficiência de Variável Comum/epidemiologia , Bases de Dados Factuais/estatística & dados numéricos , Disfunção de Fagócito Bactericida/epidemiologia , Sistema de Registros/estatística & dados numéricos , Adulto , Agamaglobulinemia/diagnóstico , Agamaglobulinemia/genética , Criança , Imunodeficiência de Variável Comum/diagnóstico , Imunodeficiência de Variável Comum/genética , Diagnóstico Tardio/estatística & dados numéricos , Feminino , Humanos , Masculino , Disfunção de Fagócito Bactericida/diagnóstico , Disfunção de Fagócito Bactericida/genética , Suíça/epidemiologiaRESUMO
A 16-month-old boy presented with failure to thrive despite sufficient caloric intake, hypersalivation, abdominal pain, chronic diarrhea and blepharitis. An eosinophilic esophagitis (EoE) was diagnosed by esophageal biopsy. Dietary restrictions and topical steroid treatment lead to no improvement. Further diagnostic work-up revealed an intrathoracal, paraspinal ganglioneuroblastoma. After operative extirpation of the tumour, all initial symptoms resolved. An esophageal control biopsy 4 weeks after tumour resection was normal. This is the first report of eosinophilic esophagitis as part of a paraneoplastic syndrome in a patient with a malignant disease other than a carcinoma.
Assuntos
Esofagite Eosinofílica/diagnóstico , Ganglioneuroblastoma/diagnóstico , Síndromes Paraneoplásicas/diagnóstico , Neoplasias da Coluna Vertebral/diagnóstico , Vértebras Torácicas , Diagnóstico Diferencial , Esofagite Eosinofílica/cirurgia , Ganglioneuroblastoma/cirurgia , Humanos , Lactente , Masculino , Síndromes Paraneoplásicas/cirurgia , Neoplasias da Coluna Vertebral/cirurgia , Tomografia Computadorizada por Raios XRESUMO
BACKGROUND: Oral mucositis (OM) is a common chemo- and radiotherapy adverse effect in oncological pediatric patients. Herpes simplex virus (HSV) infection can cause a severe clinical course. We hypothesize, that HSV seropositivity is a risk factor for local HSV-1 reactivation and increased frequency of OM in patients with myelosuppressive therapies. PATIENTS AND METHOD: We evaluated the prevalence of seropositivity of HSV-1 between June 2011 and April 2014 in patients with potential oncological disease and correlated it to the frequency of OM and local viral reactivation in OM under myelosuppressive therapy. RESULTS: The overall rate of HSV-seropositivity in our cohort was 22%. 48 patients underwent myelosuppressive therapy. Of these, 7 were HSV-1 IgG positive and 41 negative. All patients with OM under myelosuppressive therapy and positive local swab for viral HSV (l-PCR) were HSV-1 IgG positive before the start of therapy (100%). The absolute risk for OM in HSV-1 IgG positive patients was increased by 58.5% (95%CI: 20.0 - 72.2%) corresponding to a relative risk (RR) of 2.4 (95%CI: 1.7-3.5, P=0.009). The multivariable adjusted OR to suffer 2 or more OM episodes in HSV-1 IgG positivity was 8.8 (95%CI: 1.5-95.8, P=0.014). DISCUSSION AND CONCLUSION: In HSV-1 IgG positive patients half of the OM episode showed HSV reactivation, and the risk for multiple OM episodes was increased. These patients should be investigated for HSV-infection in every OM episode. Prophylactic and preemptive therapeutic measures should be discussed early, but prospective data on HSV prophylaxis and preemptive treatment is required.
Assuntos
Antineoplásicos/efeitos adversos , Neoplasias/tratamento farmacológico , Infecções Oportunistas/induzido quimicamente , Infecções Oportunistas/epidemiologia , Estomatite Herpética/induzido quimicamente , Estomatite Herpética/epidemiologia , Ativação Viral/efeitos dos fármacos , Adolescente , Anticorpos Antivirais/sangue , Antineoplásicos/uso terapêutico , Criança , Pré-Escolar , Estudos de Coortes , Estudos Transversais , Feminino , Herpesvirus Humano 1/efeitos dos fármacos , Humanos , Lactente , Masculino , Neoplasias/imunologia , Neutropenia/induzido quimicamente , Neutropenia/epidemiologia , Neutropenia/imunologia , Infecções Oportunistas/imunologia , Estudos Retrospectivos , Estatística como Assunto , Estomatite Herpética/imunologiaRESUMO
Inhibitor development is a rare but serious event in hemophilia B patients. Management is hampered by the frequent occurrence of allergic reactions to factor IX, low success rates of current inhibitor elimination protocols and the risk of development of nephrotic syndrome. Single cases of immune tolerance induction (ITI) including immunosuppressive agents like mycophenolat mofetil (MMF) or rituximab have been reported. We present a case of successful inhibitor elimination with a combined immune-modulating therapy and high-dose factor IX (FIX). This boy had developed a FIX inhibitor at the age of 5 years and had a history of allergic reactions to FIX and to FEIBAO. Under on-demand treatment with recombinant activated FVII the inhibitor became undetectable but the boy suffered from multiple joint and muscle bleeds. At the age of 11.5 years ITI was attempted with a combination of rituximab, MMF, dexamethasone, intravenous immunoglobulins and high-dose FIX. The inhibitor did not reappear and FIX half-life normalized. No allergic reaction, no signs of nephrotic syndrome and no serious infections were observed.
Assuntos
Fator IX/uso terapêutico , Hemofilia B/imunologia , Tolerância Imunológica , Imunossupressores/uso terapêutico , Ácido Micofenólico/análogos & derivados , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Murinos , Criança , Dexametasona/uso terapêutico , Humanos , Lactente , Masculino , Ácido Micofenólico/uso terapêutico , RituximabRESUMO
Our objective was to compare the ranking of dairy cows according to their methane (CH) emissions as measured by a respiration chamber (RC) technique and the GreenFeed (GF) technique during 3 periods in second lactation. Two-day CH measurements in a RC performed in wk 3, 14, and 42 of lactation were flanked by GF measurements for 20 (period 1 [P1]), 35 (period 2 [P2]), and 35 (period 3 [P3]) days, respectively, before and after RC measurement. This gave the total duration of CH measurements using the GF system of 40, 70, and 70 d for P1, P2, and P3, respectively. Mean daily CH production (g/d) of the 8 dairy cows was 346, 439, and 430 using the RC technique and 338, 378, and 416 using the GF system during P1, P2, and P3, respectively. Average daily CH production determined by the GF technique was 2.4, 13.8, and 3.2% lower in P1, P2, and P3, respectively. Methane normalized to DMI continuously increased from P1 to P3 when measured in a RC, whereas it was lowest during P2 when measured by the GF method. Ranking of the cows according to CH production, CH/energy-corrected milk yield (ECM; CH/ECM), and CH/DMI differed between periods no matter which method was used. Cluster analysis including all 3 periods, however, identified the same cows with the highest and lowest CH production determined either by the RC technique or the GF system. In conclusion, multiple CH measurements at different stages of lactation are necessary for reliable discrimination of highest and lowest CH emitting cows and the GF system may be used to discriminate the extremes.
Assuntos
Ração Animal/análise , Bovinos/fisiologia , Lactação/fisiologia , Metano/biossíntese , Fenômenos Fisiológicos da Nutrição Animal , Animais , Dieta/veterinária , Feminino , Leite/química , Fenômenos Fisiológicos RespiratóriosRESUMO
We investigated the molecular basis of glycogen storage disease type 1 non-A (GSD1 non-A) in 21patients. In addition to 8 novel mutations within the G6PT1 gene (c.250T>A, c.580G>A, c.627C>T, c.653-4delAG, c. 844C>A, c.1071A>C, c.1268G>A, c.1348G>A), we found a remarkably high prevalence of exon 8 mutations in German patients. The c.1211-2delCT mutation and the c.1184G>T mutation accounted for 32% and 29% of mutant chromosomes, respectively, supporting the hypothesis of a Middle European origin of these two mutations. Together with less common mutations, 79% of German GSD1 non-A patients were either homozygous or heterozygous for an exon 8 mutation. In addition to direct sequencing, these exon8 mutations could be detected by mutation-specific methods such as the detection of heteroduplex formation on polyacrylamide gel electrophoresis or by the amplification of DNA segments by allele-specific oligonucleotides. Furthermore, the use of denaturating high performance liquid chromatography (DHPLC) allowed a 100% detection and discrimination of all exon 8 mutations. In conclusion from these results, we recommend the use of either conventional or DHPLC screening as the initial non-invasive and efficient diagnostic procedure in patients with GSD1 non-A from populations with a similar distribution of mutations. Hum Mutat 16:177, 2000.
Assuntos
Éxons/genética , Doença de Depósito de Glicogênio Tipo I/enzimologia , Doença de Depósito de Glicogênio Tipo I/genética , Mutação/genética , Fosfotransferases/genética , Antiporters , Cromatografia Líquida de Alta Pressão , Croácia/etnologia , Análise Mutacional de DNA/métodos , Alemanha/epidemiologia , Doença de Depósito de Glicogênio Tipo I/epidemiologia , Humanos , Proteínas de Transporte de Monossacarídeos , Desnaturação de Ácido Nucleico/genética , Prevalência , Sicília/etnologiaRESUMO
One-hundred and two patients with good risk myeloid leukemia (CML first chronic phase or AML first CR) were transplanted from HLA-related donors after conditioning with (n = 45) or without anti-thymocyte globulin (ATG) (n = 57). One graft failure was observed in the non-ATG and none in the ATG group. The median time to leukocyte engraftment (> 1 x 10(9)/l) was 16 (range 12-33) in the ATG group and 17 days (range 11-29) in the non-ATG group (NS) and for platelet engraftment (> 20 x 10(9)/l) 24 and 19 days (P = 0.002), respectively. Acute GVHD grade II-IV was observed in 47% of the non-ATG and in 20% of the ATG group (P = 0.004). Grade III/IV GVHD occurred in 7% of the ATG and in 32% of the non-ATG group (P = 0.002). Chronic GVHD was seen in 36% and 67% (P = 0.005), respectively. After a median follow-up of 48 months (range 2-128), the 5-year estimated OS is 66% (95% KI: 51-81%) for the ATG group and 59% (95% KI: 46-72%) for the non-ATG group (NS). The 5-year estimated DFS is 64% (95% KI: 50-78%) for ATG and 55% (95% KI: 43-67%) for the non-ATG regimen (NS). The 5-year probability of relapse was 5% in the ATG and 15% in the non-ATG group (NS). ATG as part of the conditioning regimen leads to a significant reduction in GVHD without increase of relapse in patients with myeloid leukemia after stem cell transplantation from HLA-related donors.
Assuntos
Soro Antilinfocitário/uso terapêutico , Doença Enxerto-Hospedeiro/prevenção & controle , Transplante de Células-Tronco Hematopoéticas , Leucemia Mieloide Aguda/terapia , Leucemia Mieloide de Fase Crônica/terapia , Depleção Linfocítica/métodos , Linfócitos T/imunologia , Adolescente , Adulto , Criança , Intervalo Livre de Doença , Feminino , Doença Enxerto-Hospedeiro/etiologia , Doença Enxerto-Hospedeiro/imunologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Leucemia Mieloide Aguda/imunologia , Leucemia Mieloide de Fase Crônica/imunologia , Masculino , Pessoa de Meia-Idade , Doadores de Tecidos , Transplante HomólogoRESUMO
INTRODUCTION: Patients with Fanconi anemia (Fanc) are at risk of developing leukemia. Mutations of the group A gene (FancA) are most common. A multitude of polymorphisms and mutations within the 43 exons of the gene are described. To examine the role of heterozygosity as a risk factor for malignancies, a partially automatized screening method to identify aberrations was needed. We report on our experience with DHPLC (WAVE (Transgenomic)). METHODS: PCR amplification of all 43 exons from one individual was performed on one microtiter plate on a gradient thermocycler. DHPLC analysis conditions were established via melting curves, prediction software, and test runs with aberrant samples. PCR products were analyzed twice: native, and after adding a WT-PCR product. Retention patterns were compared with previously identified polymorphic PCR products or mutants. RESULTS AND DISCUSSION: We have defined the mutation screening conditions for all 43 exons of FancA using DHPLC. So far, 40 different sequence variations have been detected in more than 100 individuals. The native analysis identifies heterozygous individuals, and the second run detects homozygous aberrations. Retention patterns are specific for the underlying sequence aberration, thus reducing sequencing demand and costs. DHPLC is a valuable tool for reproducible recognition of known sequence aberrations and screening for unknown mutations in the highly polymorphic FancA gene.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Análise Mutacional de DNA/métodos , Anemia de Fanconi/genética , Testes Genéticos/métodos , Polimorfismo Genético , Sequência de Bases , Criança , Primers do DNA/genética , Éxons , Anemia de Fanconi/complicações , Variação Genética , Neoplasias Hematológicas/etiologia , Neoplasias Hematológicas/genética , Heterozigoto , Homozigoto , Humanos , Leucemia Mieloide Aguda/etiologia , Leucemia Mieloide Aguda/genética , Desnaturação de Ácido Nucleico , Reação em Cadeia da Polimerase , Polimorfismo de Nucleotídeo Único , Reprodutibilidade dos Testes , Fatores de RiscoRESUMO
Late malignancies have been discussed as a potential risk for growth factor mobilized donors of hematopoietic stem cells. Little is known about the incidence and potential risk factors. This single center retrospective cohort study evaluated all HLA-identical sibling pairs with hematopoietic stem cell transplantation (HSCT) for a hematological malignancy, treated from 1974 to 2001 at the University Hospital of Basel. Three hundred eighteen pairs were identified, 291 donors (92%) could be contacted. Median observation time was 13.8 years (range 5-32 years). Sixteen (5%) donors had developed a total of 18 tumors, 17 recipients a secondary tumor. According to the age- and sex-adapted cancer incidence, 3.3 tumors in male and 6.8 in female donors were expected, 3 (relative risk (RR): 0.91, 95% confidence interval: 0.19-2.66) and 4 (RR: 0.58, 95% confidence interval: 0.16-1.48), respectively, were found in donors between 0 and 49 years. Between 50 and 69 years, 4.5 tumors in males and 4.8 in females were expected, 5 (RR: 1.11, 95% confidence interval: 0.36-2.59) and 6 (RR: 1.23, 95% confidence interval: 0.45-2.67), respectively, were observed. Tumors do occur in donors of hematopoietic stem cells at least at the rate as expected in a normal population; whether incidence exceeds expected rates needs to be determined in larger international cohorts.
Assuntos
Transplante de Células-Tronco Hematopoéticas/estatística & dados numéricos , Neoplasias/epidemiologia , Doadores de Tecidos/estatística & dados numéricos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Estudos de Coortes , Feminino , Alemanha/epidemiologia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Suíça/epidemiologia , Adulto JovemRESUMO
The prognosis of patients with poor-risk or relapsed hematological malignancies is dismal. The dose intensification necessary to achieve subsequent CR is limited by the toxicity of chemotherapy. Treatment intensification with double allogeneic HSCT (dHSCT) may enhance the antileukemic effect and reduces treatment-related toxicity associated with prolonged aplasia during reinduction. We evaluated this approach in 23 patients, nine with primary refractory disease or relapse after conventional chemotherapy (group I) and 14 with relapses after allogeneic HSCT (group II). Double HSCT was feasible in all patients. At the end of the observation period, 6 of 23 (26%) patients were still alive and in remission with a median observation time of 60 months (1-153). The overall survival probability at 1 year was 41% (95% confidence interval (CI), 21-62%), transplant-related mortality (TRM) 28% (9-47%) and the incidence of relapse 42% (18-66%). The TRM in groups I and II were 22 and 36% and the relapse rate 33 and 50%, respectively. In conclusion, we have shown the feasibility of dHSCT with an acceptable TRM, irrespective of a previous allogeneic HSCT. Whether this approach offers a survival benefit for patients with poor-risk leukemias has to be tested in larger prospective trials.
Assuntos
Neoplasias Hematológicas/cirurgia , Transplante de Células-Tronco Hematopoéticas/métodos , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Doença Enxerto-Hospedeiro , Neoplasias Hematológicas/mortalidade , Transplante de Células-Tronco Hematopoéticas/mortalidade , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva , Estudos Retrospectivos , Terapia de Salvação , Condicionamento Pré-Transplante , Transplante Homólogo/mortalidadeRESUMO
BACKGROUND: Denaturing HPLC (DHPLC) can be used to screen DNA for known and unknown mutations. We describe a novel, HPLC-based method for discrimination among polyclonal, oligoclonal, and/or clonal T-cell receptor gamma (TCR-gamma) rearrangements in samples from children with newly diagnosed acute lymphoblastic leukemia. METHODS: TCR rearrangements were PCR amplified from initial leukemic samples and, after heteroduplex-induction, the clonality status of each product was evaluated. To attain this, we used DHPLC on a high-resolution micropellicular matrix. Running conditions were established by melting-curve analysis of known clonal and polyclonal products and melting-point prediction software. Elution profiles were studied at 50 degrees C (native) and, to achieve optimal separation, at different column temperatures between 56 and 64 degrees C. RESULTS: For VgammaI-Jgamma1.3/2.3 rearrangements, an analysis temperature of 60 degrees C with a linear triethylammoniumacetate-acetonitrile gradient separated clonal bands from the polyclonal background amplification. Less than 15% clonal PCR product was detectable in mixtures of initial leukemic cell DNA and polyclonal DNA. Biallelic rearrangements produced two sharp peaks. Clonality of PCR products from 100 initial leukemic samples was completely identified in all investigated cases. CONCLUSIONS: Heteroduplex analysis with standardized DHPLC conditions simplifies the detection of unknown clonal or polyclonal TCR rearrangements in newly diagnosed leukemias. Clonal targets for detection of minimal residual disease are available after a short, automated analysis of PCR amplified rearrangements.
Assuntos
Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , Receptores de Antígenos de Linfócitos T gama-delta/genética , Sequência de Bases , Cromatografia Líquida de Alta Pressão/métodos , Análise Heteroduplex , Humanos , Dados de Sequência Molecular , Reação em Cadeia da PolimeraseRESUMO
Behavioral and neurophysiological studies in macaque monkeys suggest a role of the inferior temporal cortex in pattern discrimination and visual memory. To determine whether this cortical area is also involved in human short-term visual memory, we measured spatial frequency discrimination thresholds for sequentially presented stimuli in 17 patients with unilateral, postoperative focal damage to the temporal cortex (11 left, 6 right hemisphere). These results are compared to those of 17 age-matched control subjects. Contrast detection thresholds and difference thresholds for spatial frequency were determined for spatially truncated sine wave gratings presented in the left and right visual fields. Detection thresholds were measured for sine wave gratings in a spatial two-alternative forced-choice procedure for three spatial frequencies [2.5, 5, and 10 cycles (c)/degree] for each hemifield. Discrimination thresholds were determined for two gratings sequentially presented either 4 degrees to the left or right of fixation. Grating contrast was five times the value of detection threshold and reference frequency was 5 c/degree. Within each trial, the gratings were separated in time by 1, 3, and 10 sec interstimulus intervals (ISIs), and subjects signaled which grating had the higher spatial frequency. The results indicate that (1) contrast detection thresholds overall did not differ between patient and control groups; (2) spatial frequency discrimination thresholds were, however, significantly elevated in patients and this elevation was significantly more pronounced in the visual field contralateral to the damaged hemisphere; and (3) patients with inferotemporal damage exhibited higher discrimination thresholds for the longest ISI, whereas patients with medial/superior temporal lobe damage did not show this effect. The results suggest that visual areas in human temporal cortex are involved in the higher visual processes underlying delayed pattern discrimination.
Assuntos
Encefalopatias/fisiopatologia , Reconhecimento Visual de Modelos , Lobo Temporal , Adulto , Envelhecimento/fisiologia , Análise de Variância , Encefalopatias/diagnóstico por imagem , Encefalopatias/psicologia , Sensibilidades de Contraste , Limiar Diferencial , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Psicofísica/métodos , Tempo de Reação , Tomografia Computadorizada por Raios XRESUMO
BACKGROUND: Patients with Fanconi Anemia (FANC) have a well documented increased risk to develop malignancies, especially Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). The risk for heterozygous individuals is not clear, epidemiological data are inconsistent. If the risk for heterozygous individuals to develop malignancies was increased, they should be found in groups of patients with AML or MDS at higher proportion than in the normal population. We are currently screening a pediatric population with hematologic malignancies for mutations in the FANCA, FANCC and FANCG gene, and report here on siblings carrying a heterozygous frameshift mutation in the FANCC Gene. PATIENTS AND METHODS: Using PCR based single strand conformational analysis we screened the DNA from pediatric patients suffering from 1 degree or 2 degrees MDS, CMML/JMML or AML for mutations in the FANCA (43 exons), FANCC (14 exons) and FANCG (14 exons) gene, and included one patient with refractory T-ALL, being the brother of a patient with T-ALL and MDS transforming into AML. Aberrant PCR products were directly sequenced. Flowcytometric measurement of mitogen-sensitivity and G2-phase arrest is used to evaluate cultured stimulated lymphocytes from individuals carrying FANC-mutations. RESULTS: A novel heterozygous frame-shift mutation, 377-378delGA in the FANCC gene was found in 2 siblings, both suffering from T-ALL with subsequent MDS transforming to AML in one of them. No other mutation was found by direct sequencing of the complete FANCC gene. Both patients died under therapy. The parents (first degree cousins) and one healthy brother are also carriers. Their lymphocytes show a higher mutagen sensitivity than normal, but do not get blocked in G2 phase as being typical for Fanconi Anemia. CONCLUSION: As the mutation causes a premature Stopcodon within exon 4 of the FANCC gene it has to be regarded as a causal FANCC gene defect. The findings within this family support the hypothesis of an increased risk to develop malignancies in heterozygous carriers of FANC-mutations. A systematic screening of further patients is needed, and we are currently examining a larger cohort to get a better estimate of the true risk of heterozygosity.
Assuntos
Anemia de Fanconi/genética , Mutação da Fase de Leitura , Leucemia-Linfoma de Células T do Adulto/genética , Síndromes Mielodisplásicas/genética , Análise Mutacional de DNA , Anemia de Fanconi/complicações , Evolução Fatal , Feminino , Predisposição Genética para Doença , Heterozigoto , Humanos , Leucemia-Linfoma de Células T do Adulto/etiologia , Masculino , Síndromes Mielodisplásicas/etiologia , Reação em Cadeia da Polimerase , Polimorfismo Conformacional de Fita SimplesRESUMO
We investigated the efficacy of an antithymocyte globulin/cyclophosphamide preparative regimen prior to allogeneic stem cell transplantation from HLA-identical siblings in patients with severe aplastic anemia. Since 1990, 21 patients, 6 males and 15 females, with a median age of 25 years (range: 7-43) have been enrolled in the protocol consisting of 200 mg/kg cyclophosphamide and 90-120 mg/kg antithymocyte globulin (ATG, rabbit, Fresenius, Bad Homburg, Germany). For further graft-versus-host disease (GVHD) prophylaxis all patients received cyclosporin A and a short course of methotrexate (MTX). Only one patient had a primary graft failure (5%). All other patients engrafted with a leukocyte count >1.0 x 10(9)/l and a platelet count >20 x 10(9)/l after a median of 19 (range: 11-28) and 26 days (range: 13-67), respectively. No late graft failure or relapse was observed. Two patients experienced mild acute GVHD grade I (10%), and one patient developed grade II GVHD (5%). No severe grade III/IV GVHD was observed; 17% of the patients developed limited chronic GVHD. The treatment-related mortality was 14% and mainly due to fungal infection. After a median follow-up of 70 months (range: 2-139), the estimated overall and event-free survival at 10 years for all patients is 86% (95% confidence interval: 70-100%). We conclude that ATG plus cyclophosphamide is an effective conditioning regimen in patients with aplastic anemia undergoing stem cell transplantation with a low treatment-related mortality, resulting in an excellent outcome.